Fig. 2

Blocking Th2-mediated immunity promotes Th2 to Th1 switch and inhibits tumor growth in breast cancer. A Representative contour plots and quantification of CD45⁺CD4⁺ ratios in EO771 and 4T1 tumor model (n = 5, t test). B Relative IFN-γ:IL-4 ratio of CD4⁺ T cells isolated from EO771 and 4T1 tumors treated with vehicle or IPD treatment (n = 5, t test). C T-distributed stochastic neighbor embedding (t-SNE) plot of tumor-infiltrating CD4⁺ T cells overlaid with color-coded clusters in EO771 tumors. D Frequency of clusters of indicated CD4⁺ T cells subsets (n = 3, t test). E Quantification of Th2 cell in peripheral blood cells in EO771 and 4T1 tumor models (n = 5, t test). F EO771 and 4T1 tumor growth in vehicle-treated versus IPD-treated mice (n ≥ 4, two-way ANOVA). Mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant